Plain-English translation of NCT07871097 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether rimegepant, an already-approved migraine medication, can help relieve the sudden dizziness and spinning sensations that come with vestibular migraines. Researchers want to see if this treatment can reduce both the spinning feeling and other uncomfortable symptoms that happen during these migraine attacks. You would take the medication during an actual attack and report how you feel.
Vestibular migraines—migraines that cause severe spinning and dizziness—can be really disabling, and doctors don't yet have strong evidence about the best acute treatments. This trial will help determine whether this medication works quickly to ease these symptoms when they strike.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the medication or a placebo (a fake pill) as your first treatment during a vestibular migraine attack, then switch to the other option for your next attack. This crossover design lets researchers compare how the real medication works versus placebo in the same person. You'll report your symptoms before and after taking each dose to help the study team understand whether the treatment eases your dizziness and other migraine discomforts.
AI-generated summary from trial data · Nov 4, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Wensheng Qu
Collaborators
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan No.1 Hospital
Enrollment target
~80 participants
Started
December 2025
Primary completion
November 2027
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wensheng Qu
Wensheng Qu
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.